The 41 references in paper S. Avdeev N., N. Karchevskaya А., С. Авдеев Н., Н. Карчевская А. (2014) “Первый опыт использования небулизированного тобрамицина при обострении бронхоэктазов // First experience of using nebulized tobramycin in patients with acute exacerbation of bronchiectasis” / spz:neicon:pulmonology:y:2011:i:4:p:133-138

1
Reid L.M. Reduction in bronchial subdivision in bronchiectasis. Thorax 1950; 5: 233–247.
(check this in PDF content)
2
Barker A.F.Bronchiectasis. N. Engl. J. Med. 2002, 346: 1383–1393.
(check this in PDF content)
3
Pasteur M.C., Helliwell S.M., Houghton S.J. et al.An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 1277–1284.
(check this in PDF content)
4
Cole P.J.Inflammation: a two-edged sword- the model of bronchiectais. Eur. J. Respir. Dis. 1986; Suppl. 147: 6–15.
(check this in PDF content)
5
Finklea J.D., Khan G., Thomas S. et al.Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir. Med. 2010; 104: 816–821.
(check this in PDF content)
6
Alzeer A.H., Masood M., Jani Basha S. et al. Survival of brochiectatic patients with respiratory failure in ICU. BMC Pulm. Med. 2007; 7: 17.
(check this in PDF content)
7
Dupont M., Gacouin A., Lena H. et al. Survival of patients with bronchiectasis after the first ICU stay for respiratory failure. Chest 2004; 125: 1815–1820.
(check this in PDF content)
8
Haworth C.S. Antibiotic treatment strategies in adults with bronchiectasis. Eur. Respir. Mon. 2011; 52, 211–222.
(check this in PDF content)
9
Vendrell M., de Gracia J., Olveira C. et al.Diagnosis and treatment of bronchiectasis. Arch. Bronconeumol. 2008; 44: 629–640.
(check this in PDF content)
10
Ho P.L., Chan K.N., Ip M.S.M. et al.The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594–1598.
(check this in PDF content)
11
Evans S.A., Turner S.M., Bosch B.J. et al.Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir. J. 1996; 9: 1601–1604.
(check this in PDF content)
12
Wilson C.B., Jones P.W., O'Leary C.J. et al.Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur. Respir. J. 1997; 10: 1754–1760.
(check this in PDF content)
13
Weycker D., Edelsberg J., Oster G. et al. Prevalence and economic burden of bronchiectasis. Clin. Pulm. Med. 2005; 12: 205–209.
(check this in PDF content)
14
Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130; 1503–1510.
(check this in PDF content)
15
Wood G.C., Boucher B.A.Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20: 166–181.
(check this in PDF content)
16
Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–30.
(check this in PDF content)
17
Hodson M.E., Gallagher C.G., Govan J.R.W.A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.
(check this in PDF content)
18
Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.
(check this in PDF content)
19
Cheer S.M., Waugh J., Noble S.Inhaled tobramycin (TOBI): A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs
(check this in PDF content)
20
3; 63: 2501–2520. 20.Carcas A.J., Garcia)Statue J.L., Zapater P., Frias)Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin. Pharmacol. Ther. 1999; 65: 245–250.
(check this in PDF content)
21
Goldstein I., Wallet F., Nicolas)Robin A. et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 2002; 166: 1375–1381.
(check this in PDF content)
22
Makhoul I.R., Merzbach D., Lichtig C., Berant M. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: Comparison of aerosol and systemic administration. J. Infect. Dis. 1993; 168: 1296–1299.
(check this in PDF content)
23
Kahler D.A., Schowengerdt K.O., Fricker F.J. et al.Toxic serum trough concentrations after administration of nebulized tobramycin. Pharmacotherapy 2003; 23: 543–545.
(check this in PDF content)
24
Angrill J., Agusti C., de Celis R. et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–19.
(check this in PDF content)
25
Murray P.R., Washington J.A. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.
(check this in PDF content)
26
Palmer L.B., Smaldone G.C., Simon S.R. et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit. Care Med. 1998; 26: 31–39.
(check this in PDF content)
27
Goldstein I., Chastre J., Rouby J.J. Novel and innovative strategies to treat ventilator-associated pneumonia: optimizing the duration of therapy and nebulizing antimicrobial agents. Semin. Respir. Crit. Care Med. 2006; 27: 82–91.
(check this in PDF content)
28
Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.
(check this in PDF content)
29
Le Conte P., Potel G., Peltier P. et al.Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 1993; 147: 1279–1282.
(check this in PDF content)
30
Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 2009; 28: 253–259.
(check this in PDF content)
31
Ilowite J.S., Gorvoy J.D., Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987; 136: 1445–1449.
(check this in PDF content)
32
Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir. Care 2007; 52: 866–884.
(check this in PDF content)
33
Conrad D.J. The clinical use of aerosolized antibiotics. Clin. Pulm. Med. 2003; 10: 201–207.
(check this in PDF content)
34
Chuchalin A., Amelina E., Bianco F.Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements. Pulm. Pharm. Ther. 2009; 22: 526–532.
(check this in PDF content)
35
Knowles M.R., Robinson J.M., Wood R.E. et al.Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588–2595.
(check this in PDF content)
36
Barker A.F., Couch L., Fiel S.B. et al.Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 481–485.
(check this in PDF content)
37
Couch L.A.Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001; 120 (Suppl.): 114S–117S.
(check this in PDF content)
38
Scheinberg P., Shore E.A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420–1426.
(check this in PDF content)
39
Study to See if AZLI (an Inhaled Antibiotic) is Effective in Treating Adults With Non-CF Bronchiectasis – AIR-BX2. http:// clinicaltrials.gov/ct2/show/NCT01314716.
(check this in PDF content)
40
Bilton D., Bruinenberg P., Otulana B. et al.Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Am. J. Respir. Crit. Care Med. 2009; 179: A3214.
(check this in PDF content)
41
O'Donnell A.E., Swarnakar R., Yahina L. et al. A placebocontrolled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur. Respir. J. 2009; 34: 231S.
(check this in PDF content)